Peregrine portfolio company Cordio Medical has launched a pilot of its HearO™ platform with AstraZeneca and Bellvitge University Hospital in Spain. The pilot will evaluate HearO’s ability to remotely monitor patients with congestive heart failure (CHF), including patient adherence and the platform’s ability to provide early warning of clinical deterioration. HearO uses speech signal processing and artificial intelligence to detect changes in a patient’s voice associated with fluid accumulation, an early sign of worsening heart failure. Previous studies in Israel and the U.S. demonstrated an 82% success rate in predicting a heart decompensation event up to 22 days in advance.
Media coverage: Hospital Management
